Sanofi, GSK keep the ball rolling with da­ta on sec­ond-gen Covid vac­cine can­di­date

Sanofi and GSK are keep­ing the R&D en­gine churn­ing for Covid-19 vac­cines.

The part­ners, which have yet to get their first shot on the mar­ket, re­port­ed that their next-gen­er­a­tion boost­er — mod­elled on the Be­ta vari­ant of the SARS-CoV-2 virus and in­cor­po­rat­ing GSK’s ad­ju­vant — kicked up a stronger im­mune re­sponse to adults who re­ceived mR­NA jabs than both its own first-gen­er­a­tion shot and Pfiz­er/BioN­Tech’s Comir­naty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER